Biotech Values

[ghmm]

I am not a shareholder but have listened to several of their calls. I think Paul is VERY direct and though I have never called him think he would be very open to talking to shareholders (from comments on calls).

My concern is that he seems like a gambler and I still think stroke is risky especially their trial since their window is longer (believe it is 6 hours) so I wonder if they will get patients that are more advanced?

I liked the company for the (small) Nemanda royalty, had another small drug for brain edema that they licensed out (to find their stroke trial) and they have a MUCH bigger royalty for Nemanda if it is developed in I believe a couple other indications.

Well it never got cheap enough for me so I am not holding. I would prefer some more risk off the table before investing here.